About 28 results found for searched term "TP-7" (0.052 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1759 | GSK1120212 (Trametinib) | MEK |
| JTP-74057, GSK212 | ||
| Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis. | ||
| M2432 | Bardoxolone Methyl | IκB/IKK |
| RTA 402, TP-155, NSC 713200,CDDO Methyl ester | ||
| Bardoxolone Methyl is an IKK inhibitor with potent pro-apoptotic and anti-inflammatory activities, as well as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway. | ||
| M4890 | JZL 195 | MAGL |
| GTPL8606, KB-78011 | ||
| JZL195 is an effective FAAH and MAGL inhibitor with IC50 of 2 nM and 4 nM, respectively. | ||
| M6139 | GSK2256098 | FAK |
| GTPL7939 | ||
| GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. | ||
| M7466 | VTP-27999 | Others |
| VTP-27999 is a highly potent and selective renin inhibitor with IC50 of 0.47 nM. | ||
| M8603 | GSK484 hydrochloride | PAD |
| GTPL8577; AOB6992 | ||
| GSK484 hydrochloride is a potent selective reversible inhibitor of protein arginine deiminase PAD4, an enzyme believed to play a role in granulocyte and macrophage development leading to inflammation and immune response, and overexpressed in many tumors. | ||
| M8739 | TP-472N | Others |
| TP-472N is a negative control probe for TP-472 (catalog no. | ||
| M9265 | Vimirogant | ROR |
| AGN-242428; VTP-43742; RORγ-IN-1 | ||
| Vimirogant (also known as AGN-242428 and VTP-43742) is a potent, selective and orally active RORγt inhibitor. | ||
| M9483 | Azeliragon | Others |
| TTP488; PF-04494700 | ||
| Azeliragon is a potent and orally active RAGE inhibitor. | ||
| M9515 | MS417 | Epigenetic Reader Domain |
| GTPL7512 | ||
| MS417 (also known as GTPL7512) is a potent and selective BRD4 inhibitor, which binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30 and 46 nM, respectively. | ||
| M14172 | Trametinib (DMSO solvate) | MEK |
| GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate) | ||
| Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. | ||
| M20633 | TP0427736 HCl | Src-bcr-Abl |
| TP0427736 is a potent inhibitor of ALK5 kinase activity with an IC50 of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC50 = 836 nM for ALK3). It also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM. | ||
| M24699 | Vandortuzumab vedotin | Antibody-Drug Conjugates (ADCs) |
| DSTP 3086S; RG 7450; MSTP2109A | ||
| Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. | ||
| M27638 | VTP-27999 TFA | Renin |
| VTP-27999 TFA is an alkyl amine Renin inhibitor; VTP-27999 TFA is useful for Hypertension and End-Organ Diseases. | ||
| M28095 | VTP-27999 Hydrochloride | Renin |
| VTP-27999 Hcl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases. IC50 value: Target: Renin | ||
| M28133 | TP-7 | Peptides |
| Selanc; Selank | ||
| TP-7 (Selanc) is a heptapeptide with anxiolythic properties. | ||
| M28619 | TP-6076 | Antibiotic |
| TP-6076 is a fully synthetic fluorocycline antibiotic, acts function via binding to the 30S ribosomal subunit and maintains its activity. TP-6076 displays potent mechanism-based antitranslational activity (Tet protein, IC50=0.18 μg/mL), shows a wide range of antimicrobial and antiparasitic activities. | ||
| M29172 | TP-472 | Epigenetic Reader Domain |
| TP-472 is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7. TP-472 induces apoptosis of melanoma cells. | ||
| M29749 | TP0597850 | MMP |
| TP0597850 is a selective inhibitor of MMP2 (IC50=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t1/2=265 min). | ||
| M30686 | TPI-287 | Microtubule |
| TPI-287, a blood-brain barrier-permeable microtubule stabilizer, can significantly reduce metastatic colonization of breast cancer in the brain. | ||
| M30963 | TTP-8307 | Anti-infection |
| TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP). | ||
| M31061 | Vimirogant hydrochloride | ROR |
| VTP-43742 hydrochloride | ||
| Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. | ||
| M40585 | TTP273 | GLP Receptor |
| TTP273 is a GLP-1R agonist that can be used in studies related to type 2 diabetes. | ||
| M40620 | TP0472993 | Cytochrome P450 (e.g. CYP17) |
| TP0472993 is a novel, orally active, selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis that inhibits the production of 20-HETE, thereby reducing the ERK1/2 and STAT3 signaling pathways, and ultimately inhibiting the progression of renal fibrosis. It can be used in studies related to chronic kidney disease (CKD). | ||
| M41432 | TP-1287 | CDK |
| TP-1287 is an orally active CDK9 inhibitor. | ||
| M43569 | YTP-17 | YAP |
| YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC50 of 4 nM. | ||
| M56763 | TPN171 | PDE |
| TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH). | ||
| M56585 | JTP-103237 | Transferase |
| JTP-103237 is a MGAT2 inhibitor (IC50: 0.019 μM and 6.423 μM for hMGAT2 and hMGAT3 respectively). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
